Cellid, Co., Ltd. (KOSDAQ:299660)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,245.00
+250.00 (6.26%)
Aug 8, 2025, 3:30 PM KST
6.26%
Market Cap117.86B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out29.50M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,022,223
Average Volume1,682,759
Open4,020.00
Previous Close3,995.00
Day's Range3,965.00 - 4,330.00
52-Week Range2,712.97 - 17,310.00
Beta1.70
RSI41.56
Earnings Daten/a

About SolarWinds

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2006
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 299660
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.